Glenmark to mkt Pravastatin Sodium,Naproxen Sodium,Naproxen

RELATED NEWS OPM close to 30%; US biz key driver: Glenmark Pharma Glenmark set to ink multi-billion dollar research deals Glenmark Pharma likely to touch Rs 750 ALSO READ See latest News about Glenmark See previous management interviews See what other Experts & Brokerages are saying about Glenmark Glenmark BSE | NSE 10/02/12 Are Mutual Funds betting on Glenmark?

Glenmark Pharmaceuticals Ltd [Glenmark], a research-based company headquartered in Mumbai (India) received US FDA approval to market Pravastatin Sodium oral tablets 10 mg, 20 mg and 40 mg, a generic version of Bristol Myers Squibb brand Pravachol that has annual sales of over USD 861  million.  Glenmark is manufacturing the finished dose formulation at its USFDA approved manufacturing facility in Goa, India. Glenmark's US subsidiary, Glenmark Pharmaceuticals Inc ., USA [GPI] is responsible for marketing the product in the US and will commence supplies of the drug to customers immediately.

 

In the preceding month, Glenmark also received US FDA approval to market Naproxen Sodium oral tablets EQ 250 mg and 500 mg base, a generic version of Roche's brand Anaprox and Naproxen oral tablets 250 mg, 375 mg and 500 mg, a generic version of Hoffmann-La Roche AG brand Naprosyn. The drugs have annual sales of USD 13 million and USD 53 million respectively.  These drugs are also manufactured at Glenmark's Goa facility and will be marketed in the US by GPI.

 

With these approvals, Glenmark's subsidiary GPI will have 15 generic products in the US market. The Company has over 35 ANDAs undergoing US FDA approval process/launch.

  

Sourced From: Glenmark Pharmaceuticals Limited